Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

Overview of attention for article published in Nature Medicine, March 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 44 news outlets
blogs: 3 blogs

twitter: 216 X users
facebook: 3 Facebook pages

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 42 Mendeley

Summary News Blogs X Facebook Dimensions citations

So far, Altmetric has seen 255 X posts from 216 X users, with an upper bound of 2,300,794 followers.

RT @ScottGottliebMD: Two new studies show promising results for the use of engineered ‘CAR-T’ cells in the treatment of glioblastoma, exten…

24 Apr 2024

Reply Repost Favourite

BRAIN: a phase 1 study of EGFR + IL13Rα2 directed CAR-T cells showed promising results with reductions in tumour size in all 6 patients treated (although none met criteria for ORR). https://t.co/ofgdb934Q0

24 Apr 2024

Reply Repost Favourite

RT @NatureMedicine: At the #AACR24 #CellTherapies in solid tumors session? Check out our 2 recent trials on #CARTcells in patients with #gl…

11 Apr 2024

Reply Repost Favourite

RT @NatureMedicine: At the #AACR24 #CellTherapies in solid tumors session? Check out our 2 recent trials on #CARTcells in patients with #gl…

08 Apr 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 251 additional X posts.